FOLH1 and pachyonychia congenita: Among these biomarkers, PSMA is one of the most well-known and clinically validated biomarkers that is expressed 1000-fold more on PC tumors than normal prostatic tissue (Ghosh and Heston, 2004; Jeitner et al., 2022).